Other languages Navidea Biopharmaceuticals, Inc.

Equities

NAVB

US63937X2027

Delayed OTC Markets Other stock markets 12:01:12 2024-06-03 pm EDT			5-day change	1st Jan Change
0.0001 ^USD	0.00%		0.00%	-99.82%

2023	Navidea Biopharmaceuticals, Inc. announced that it expects to receive $0.75 million in funding	CI
2023	Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release	Dec. 04
Navidea Biopharmaceuticals, Inc. announced that it expects to receive $0.75 million in funding	Nov. 26
Navidea: Q3 Earnings Snapshot	Nov. 15
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Navidea Biopharmaceuticals, Inc.(OTCPK:NAVB) dropped from S&P TMI Index	23-10-11
Sector Update: Health Care	23-10-06
Top Midday Decliners	23-10-06
Navidea Biopharmaceuticals Says NYSE American Panel Upheld Delisting Decision	23-10-06
Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock	23-10-05
Navidea Biopharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11
Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel	23-08-10
Navidea Biopharmaceuticals, Inc. Announces Resignation of Malcolm G. Witter as Director, Member of the Audit Committee and Compensation, Nominating and Governance Committee of the Board	23-08-08
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination	23-07-31
Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities	23-07-31
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination	23-07-28
Navidea Biopharmaceuticals, Inc. Announces Executive Changes	23-07-28
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer	23-07-27
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer	23-07-27
Navidea Biopharmaceuticals, Inc. Announces Board Changes	23-07-13
Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down	23-07-13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Navidea Biopharmaceuticals, Inc.

Equities

NAVB

US63937X2027

Other languages

Filters